Bio Logic MateTM clinical performance test for IFX Efficacy prediction

Bio Logic MateTM clinical performance test for IFX Efficacy prediction - Bio Logic MateTM clinical performance test for IFX Efficacy prediction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009088

Enrollment

150

Registered

2012-10-12

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

IFX plus methotrexate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with RA diagnosed according to the criteria of 1987 ACR and 2010ACR/EULAR. 2. Aged 20 to 75 years at registration. 3. Written informed consent. 4. DAS28-ESR score>=3.2 at the time of entry.

Exclusion criteria

Exclusion criteria: 1. Be against the guideline of IFX and MTX. 2. Paitient is otherwise ineligible to participate in this study in the investigator's opinion.

Design outcomes

Primary

Measure	Time frame
ADAMTS5mRNA dose at 0W estimation at 14W(DAS28).	—

Secondary

Measure	Time frame
CDAI,SDAI,Boolean Definition estimation at 14W(CDAI,SDAI,Boolean Definition)estimation at 52W(CDAI,SDAI,Boolean Definition).	—

Countries

Japan

Contacts

Public ContactACRO

NPO Advanced Clinical Research Organization ACRO

biologic-mate@npo-acro.jp042-352-7676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026